<!DOCTYPE html><html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"><meta name="format-detection" content="telephone=no"><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no"><link rel="stylesheet" href="css/main.min.css"><script src="js/all.min.js"></script><script type="text/javascript">var slideNumber = 5</script></head><body class="s5"><div class="content-wrap"><nav><div onclick="iRep.go(1)" class="home-button"></div><ul><li onclick="iRep.go(3)" class="real-world-evidence"><span>REAL WORLD</span></li><li onclick="iRep.go(4)" class="evidence active"><span>EVIDENCE</span></li><li onclick="iRep.go(12)" class="reversal"><span>REVERSAL</span></li><li onclick="iRep.go(14)" class="take-action"><span>COST</span></li><li onclick="iRep.goToolbox()" class="toolbox"><span>TOOLBOX</span></li><li onclick="iRep.go(16)" class="pi"><span>PI</span></li></ul></nav><div class="page-nav"><div onclick="iRep.nextSlide()" class="page-next"></div><div onclick="iRep.prevSlide()" class="page-prev"></div></div><article><h3>Evidence<span class="sep">-</span>based anticoagulation</h3><div class="sub-title">Number of patients studied at lower doses in pivotal trials <br/> (RE<span class="sep">-</span>LY, ARISTOTLE and ROCKET AF)</div><div class="woman"></div><div class="charts"><div class="text">Pradaxa<sup>&reg;</sup> 110mg b.d.<sup>1--3</sup></div><div class="text">Apixaban 2.5mg<sup>4</sup></div><div class="text">Rivaroxaban 15mg<sup>5,6</sup></div><div class="num">6,015(33%)</div><div class="num num2">428(2%)</div><div class="num num3">1,474(10%)</div><div class="chart"><div onclick="iRep.go(6)" class="link1"></div><div onclick="iRep.go(7)" class="link2"></div><div onclick="iRep.go(8)" class="link3"></div></div><div class="nums num-1">6,015/18,113</div><div class="nums num-2">428/18,201</div><div class="nums num-3">1,474/14,264</div><div class="bottom-text">Clinical trial comparison adepted from references.<sup>1-6</sup></div></div></article><div class="overlay"></div><div class="sidebar"><ul><li class="posthoc-tab tab"></li><li class="references-tab tab"></li></ul><div class="panel"><div class="close-button"></div><div class="content references"><div class="text"><b>References: 1.</b> Connolly SJ,<em> et al. N Engl J Med</em> 2009;361:1139–1151.<b> 2.</b> Connolly SJ,<em> et al. N Engl J Med</em> 2010;363:1875–1876.<b> 3.</b> Connolly SJ,<em> et al. N Engl J Med</em> 2014;371:1464–1465.<b> 4.</b> Granger CB,<em> et al. N Engl J Med</em> 2011;365:981–992.<b> 5.</b> Patel MR,<em> et al. N Engl J Med</em> 2011;365:883–891.<b> 6.</b> Fox KAA,<em> et al. Eur Heart J<br/></em> 2011;32:2387–2394.<b> 7.</b> Data on file DBG 15-04; Patient Data, IMS Information Solutions UK Ltd, June 2015.</div></div><div class="content posthoc"><div class="text">UK data show a significant proportion of patients prescribed <br/>NOACs* are on the lower doses<sup>7</sup></div><div class="buttons"></div><div class="text2">*All indications, IMS data June 2014 – MAT June 2015. Information on rivaroxaban 2.5 mg not included as this dose accounted <br/> for 0.1% of all rivaroxaban Rx issued in MAT June 2015.</div></div></div></div></div></body></html>